Genistein induces growth arrest and suppresses telomerase activity in brain tumor cells

Genes Chromosomes and Cancer

Volumn 51, Issue 10, 2012, Pages 961-974

  Khaw, Aik Kia ^a   Yong, Jacklyn Wei Yan ^a   Kalthur, Guruprasad ^a,b   Hande, M Prakash ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KASTURBA MEDICAL COLLEGE   (India)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GENISTEIN; LIPOCORTIN 5; TELOMERASE;

ARTICLE; BRAIN TUMOR; CELL CYCLE; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; GENE EXPRESSION; GLIOBLASTOMA; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE SHORTENING; TUMOR CELL;

ANNEXIN A5; ANTICARCINOGENIC AGENTS; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; DNA DAMAGE; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; GLIOBLASTOMA; HUMANS; MEDULLOBLASTOMA; MUTATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SINGLE-CELL ANALYSIS; TELOMERASE; TELOMERE; TELOMERE SHORTENING; TUMOR CELLS, CULTURED;

EID: 84864756895     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21979     Document Type: Article

References (43)

1. Alhasan SA, Aranha O, Sarkar FH. 2001. Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin Cancer Res 7: 4174-4181.
2. Bouker KB, Hilakivi-Clarke L. 2000. Genistein: Does it prevent or promote breast cancer? Environ Health Perspect 108: 701-708.
3. Casagrande F, Darbon JM. 2000. p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp Cell Res 258: 101-108.
4. Chen WF, Huang MH, Tzang CH, Yang M, Wong MS. 2003. Inhibitory actions of genistein in human breast cancer (MCF-7) cells. Biochim Biophys Acta 1638: 187-196.
5. Chinni SR, Alhasan SA, Multani AS, Pathak S, Sarkar FH. 2003. Pleotropic effects of genistein on MCF-7 breast cancer cells. Int J Mol Med 12: 29-34.
6. Choi YH, Lee WH, Park KY, Zhang L. 2000. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91: 164-173.
7. Darbon JM, Penary M, Escalas N, Casagrande F, Goubin-Gramatica F, Baudouin C, Ducommun B. 2000. Distinct Chk2 activation pathways are triggered by genistein and DNA-damaging agents in human melanoma cells. J Biol Chem 275: 15363-15369.
8. Faqi AS, Johnson WD, Morrissey RL, McCormick DL. 2004. Reproductive toxicity assessment of chronic dietary exposure to soy isoflavones in male rats. Reprod Toxicol 18: 605-611.
9. Farina HG, Pomies M, Alonso DF, Gomez DE. 2006. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep 16: 885-891.
10. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J. 1995. The RNA component of human telomerase. Science 269: 1236-1241.
11. Greider CW, Blackburn EH. 1987. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51: 887-898.
12. Greider CW, Blackburn EH. 1989. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 337: 331-337.
13. Ishikawa K, Koyama-Saegusa K, Otsuka Y, Ishikawa A, Kawai S, Yasuda K, Suga T, Michikawa Y, Suzuki M, Iwakawa M, Imai T. 2006. Gene expression profile changes correlating with radioresistance in human cell lines. Int J Radiat Oncol Biol Phys 65: 234-245.
14. Jagadeesh S, Kyo S, Banerjee PP. 2006. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res 66: 2107-2115.
15. Jefferson WN, Padilla-Banks E, Newbold RR. 2007. Disruption of the developing female reproductive system by phytoestrogens: genistein as an example. Mol Nutr Food Res 51: 832-844.
16. Jian L. 2009. Soy, isoflavones, and prostate cancer. Mol Nutr Food Res 53: 217-226.
17. Jin CY, Park C, Kim GY, Lee SJ, Kim WJ, Choi YH. 2009. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact 180: 143-150.
18. Keith WN, Bilsland A, Hardie M, Evans TR. 2004. Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat Clin Pract Oncol 1: 88-96.
19. Kim EJ, Shin HK, Park JH. 2005. Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: A possible mechanism of the growth inhibitory effect of Genistein. J Med Food 8: 431-438.
20. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
21. Lamartiniere CA. 2000. Protection against breast cancer with genistein: A component of soy. Am J Clin Nutr 71: 1705S-1707S.
22. Li Y, Liu L, Andrews LG, Tollefsbol TO. 2009. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int J Cancer 125: 286-296.
23. Li Z, Li J, Mo B, Hu C, Liu H, Qi H, Wang X, Xu J. 2008. Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol Toxicol 24: 401-409.
24. Luo H, Jiang BH, King SM, Chen YC. 2008. Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr Cancer 60: 800-809.
25. Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, Hirata H, Li LC, Zhao H, Okino ST, et al. 2008. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 68: 2736-2744.
26. Mitchell JR, Wood E, Collins K. 1999. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402: 551-555.
27. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. 1997. Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959.
28. Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y, Uemura H. 2005. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 12: 73-80.
29. Parkinson EK, Minty F. 2007. Anticancer therapy targeting telomeres and telomerase: Current status. BioDrugs 21: 375-385.
30. Puli S, Lai JC, Bhushan A. 2006. Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J Neurooncol 79: 135-142.
31. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG. 2006. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6: 107.
32. Rucinska A, Gabryelak T. 2009. Effect of genistein-8-C-glucoside from Lupinus luteus on DNA damage assessed using the comet assay in vitro. Cell Biol Int 33: 247-252.
33. Rucinska A, Kirko S, Gabryelak T. 2007. Effect of the phytoestrogen, genistein-8-C-glucoside, on Chinese hamster ovary cells in vitro. Cell Biol Int 31: 1371-1378.
34. Schmidt F, Knobbe CB, Frank B, Wolburg H, Weller M. 2008. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. Oncol Rep 19: 1061-1066.
35. Sha GH, Lin SQ. 2008. Genistein inhibits proliferation of human endometrial endothelial cell in vitro. Chin Med Sci J 23: 49-53.
36. Shay JW, Bacchetti S. 1997. A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791.
37. Shay JW, Wright WE. 2002. Telomerase: A target for cancer therapeutics. Cancer Cell 2: 257-265.
38. Shay JW, Wright WE. 2005. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 7: 1-2.
39. Shippen-Lentz D, Blackburn EH. 1990. Functional evidence for an RNA template in telomerase. Science 247: 546-552.
40. Thasni KA, Rojini G, Rakesh SN, Ratheeshkumar T, Babu MS, Srinivas G, Banerji A, Srinivas P. 2008. Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status. Eur J Pharmacol 588: 158-164.
41. Vulliamy TJ, Knight SW, Mason PJ, Dokal I. 2001. Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita. Blood Cells Mol Dis 27: 353-357.
42. Yu GL, Bradley JD, Attardi LD, Blackburn EH. 1990. In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature 344: 126-132.
43. Yu JY, Lee JJ, Lim Y, Kim TJ, Jin YR, Sheen YY, Yun YP. 2008. Genistein inhibits rat aortic smooth muscle cell proliferation through the induction of p27kip1. J Pharmacol Sci 107: 90-98.